Novartis presented the updated study results of the MONALEESA-3 trial. Kisqali plus fulvestrant showed a significant overall survival (OS) of more than five and half years when given as first-line therapy in postmenopausal women living with HR+/HER2 breast cancer.
Kisqali plus fulvestrant increased the survival benefit by sixteen months compared to fulvestrant alone when given as first-line therapy. Further, Kisqali is the only CDK4/6 inhibitor-fulvestrant combination that demonstrated overall survival when administered as first-line therapy. Additionally, Novartis announced that among the CDK4/6 inhibitors, Kisqali had demonstrated the longest overall survival irrespective of combination partner, line of treatment, menopausal status, or site, and the number of metastases.
Novartis presented the updated data of MONALEESA-3; after a median follow-up of five years in the first-line setting, Kisqali plus fulvestrant combination showed an overall survival of 67.6 months compared to 51.8 months in patients who were administered with fulvestrant alone.
Pfizer presented the real-world evidence data of Ibrance (palbociclib) in combination with an aromatase inhibitor (AI) in patients with HR+/HER2-metastatic breast cancer (mBC).
The median progression-free survival was 49.1 months in Ibrance + aromatase inhibitor group compared to 43.2 months in the aromatase inhibitor group. The median progression-free survival was 19.3 months versus 13.9 months in patients on an aromatase inhibitor.